The GiveWell Blog

2014 plan for GiveWell’s traditional (“top charities”) work

As discussed in our previous post, in 2013, we hoped to maintain the quality of our traditional research and recommendations while spending limited senior staff time (note 1) on our traditional work. This year, we plan to put significantly more total staff time (though roughly the same amount of senior staff time) into this work.

Beyond the additional research we do, an overarching goal remains building capacity for our traditional research and recommendations. Last year, we reduced the amount of senior staff time necessary for GiveWell’s traditional work, and we hope to reduce it further this year by continuing to train staff to take over the roles filled by senior staff in the past.

In addition to the new charities and interventions we plan to consider (discussed below), we will also continue to publish updates on our past top charities: GiveDirectly, the Schistosomiasis Control Initiative, the Deworm the World Initiative (led by Evidence Action), and the Against Malaria Foundation. We will also maintain our “open-door policy” so that any organization that believes it is a strong contender for our recommendations can apply via our application page.

Given our current capacity, we anticipate being able to consider 5 or more potential top charities and 5-10 additional interventions. We are also undertaking more experimental work that might lead to additional GiveWell top charities in the future.

Our plan for our traditional work is substantially more ambitious than what we planned last year (and than what we did – evaluate 1 new top charity and a few additional interventions, most of which we hope to publish material on shortly). This reflects our substantially increased staff, discussed in the previous post.

Research priorities
Below, we list our preliminary choices for charities and interventions to prioritize.

Priority charities

While maintaining our “open door” policy, we also plan to actively pursue investigations of several particularly promising charities. We believe that, due to our growing influence and improved processes, we will be able to get a greater level of engagement from charities we actively prioritize than we have in the past.

We chose charities primarily based on our best guess at the likelihood of eventually becoming a top-rated organization (often informed by our past interactions with the charity in question). We also gave additional weight to organizations that we guessed could plausibly be significantly better than our current top charities.

To arrive at this list, we (a) reviewed our full list of eligible organizations (i.e., charities running priority programs; (b) searched the Gates Foundation (the primary major funder focused on global health) grants database; (c) conducted Google searches for organizations working on our priority interventions (listed below).

We also plan to conduct the following charity-related research:

All of our current top charities are relatively small (annual budgets of up to approximately $10 million) and – with the exception of Evidence Action – focus on only one program. With the exception of the Against Malaria Foundation, all of the charities we have recommended since 2011 have been run by people with academic backgrounds.

These characteristics are not strict criteria of ours, but recognition of the fact that they are shared by our current top charities leads us to believe that (a) these characteristics are a reasonable way to prioritize organizations and (b) working with organizations that don’t match these characteristics will likely be more time consuming. Our 2014 plans reflect this judgment. Most simply, we have prioritized organizations that pattern match our current top charities (i.e., ICCIDD and CNTD).

Priority intervention reports

We are currently near publication of a number of reports:

  • Supplemental maternal and neonatal tetanus immunization campaigns
  • Salt iodization
  • Vitamin A supplementation
  • Polio eradication

In 2014, we aim to complete 5-10 additional reports, roughly prioritized in the order below. We prioritized programs based on a combination of (a) our best guess at their cost-effectiveness and (b) the likelihood that, if we were to determine that an intervention is particularly promising, we could then find a charity implementing it to review and recommend.

To create this list, we aimed to cast a wide net, reviewing the interventions listed in (a) the Disease Control Priorities Report, (b) WHO-Choice, (c) the Copenhagen Consensus, and (d) the Lancet series on nutrition. An excel file with all interventions listed is available here.

  • Nutrition programs
    • Iron fortification/supplementation
    • Folate fortification/supplementation
    • Zinc fortification/supplementation
    • Multi-vitamin fortification/supplementation (e.g., Sprinkles)
    • Others including maternal multiple micronutrient for pregnant/fertile women and calcium for pregnant/fertile women
  • Behavior change:
    • Community-led total sanitation
    • Handwashing promotion
    • Condom promotion
    • Breastfeeding promotion
  • Prevention of mother-to-child transmission of HIV (PMTCT)
  • Oral rehydration therapy (with or without zinc)
  • Treatments for HIV/AIDS, malaria, or pneumonia
  • Intermittent preventive treatment of malaria for pregnant women (IPTp)

Experimental work to “seed” potential additional top charities

A major obstacle we face in our traditional work is the lack of charities that will likely be able to meet our criteria.

In light of this, we are working on several projects this year that are relatively experimental and may eventually lead to new top charities.

In January 2014, Good Ventures made a $100,000 grant to New Incentives, an organization focused on conditional cash transfers. New Incentives is a startup organization and does not currently qualify as a potential GiveWell top charity, but because it (a) runs a program that has significant evidence supporting it and (b) we believe that its founder, Svetha Janumpalli, is committed to allowing us to thoroughly vet her activities, we believe it is plausible that New Incentives will eventually become a GiveWell top charity. We are open to recommending other grants to other groups meeting similar criteria, if we come across them.

We would also guess that there are interventions that (a) could be considered priority programs if they had additional evidence supporting them and (b) could be scaled with additional funding. We intend to speak with organizations that conduct research (including Innovations for Poverty Action, among others) as well as Evidence Action (whose mission is to scale up evidence-based programs) to determine whether there are any interventions for which this is the case. If we identify strong contenders, we (in partnership with Good Ventures) will consider funding this research.

Finally, aside from the charities listed above, we know of no organizations focused on implementing priority programs. Engaging with large “mega-charities” has always posed a challenge for us for two reasons: (a) they tend to have large public relations and fundraising departments from which we have struggled to get helpful programmatic information and (b) because they run so many programs, we have struggled to feel confident that a donation restricted to “Program X” would in fact lead to more of Program X being implemented. On the other hand, we recognize that many major funders work directly with these large entities to implement programs, and while we know that such an investigation would be time consuming, we may now be at the point in our development where it is worthwhile.

We have not yet decided to move forward with engaging with a mega-charity; our plan is to first complete the necessary intervention reports and then assess whether any interventions/mega-charities appear to be sufficiently promising to be worth addressing the inherent challenges of this investigation.


Note 1: In this post, senior staff refers to Elie, Holden, and Alexander.

2013 progress on GiveWell’s traditional (“top charities”) work

This is the second post (of six) we’re planning to make focused on our self-evaluation and future plans.

This post reviews last year’s progress on our traditional work of finding and recommending evidence-based, thoroughly vetted charities that serve the global poor. It has two parts. First, we look back at the plans we laid out in early 2013 and compare our progress against them. Then, we reflect on the state of our traditional work and what we learned about it in 2013.

Note: in past years, we answered a series of questions about GiveWell’s progress as a donor resource and as a project. Considering that template this year, we feel that those questions (which we first used in our 2009 annual review) have become stale and no longer represent the best approach to evaluating our progress. Instead, we quote from last year’s writeup on plans and goals for the year, and compare to our actual progress during the year.

Summary

At the beginning of 2013, we felt that our traditional research and recommendations were relatively strong and would remain a valuable resource with limited effort put into improving them. We therefore aimed to limit senior staff time (note 1) on it to enable progress on GiveWell Labs.

We ultimately spent significantly more senior staff time on our traditional work than we had anticipated, which we felt was necessary to maintain the quality of our research, though we did achieve our big-picture goal of allocating more senior staff time to GiveWell Labs than previously and making more progress on that front.

We kept our research up to date, including major updates on our top charities, and added a new top charity. We also hired 6 additional research analysts, which should enable us to increase the capacity devoted to our traditional work in the future. Growth in web traffic and donations remained strong (details in our forthcoming metrics post).

Media attention to our traditional work has increased, and we now see it as both more important and more challenging to sustain this work in the future. We expect substantially more production next year, due to our increased capacity and better success getting engagement from charities (more in the next post).

Our progress in 2013
In our 2013 plan, we wrote:

The items that we consider essential for our “traditional” work are:

  • Continuing to do charity updates … on our existing top charities.
  • Reviewing any charity we come across that looks like it has a substantial chance of meeting our traditional criteria as well as, or better than, our current #1 charity (which would require not only that the charity itself has outstanding transparency, but also that the intervention it works on has an outstanding academic evidence base). We have created an application page for charities that believe they can meet these criteria.
  • Hiring. As mentioned previously, we believe our process has reached a point where we ought to be able to hire, train and manage people to carry it out with substantially reduced involvement from senior staff. We are currently hiring for the Research Associate role, and if we could find strong Research Associates we would be able to be more thorough in our traditional work at little cost to GiveWell Labs.

Below, we review each, in turn.

  • Charity updates. We had relatively long histories with each of our 3 top charities, and expected that periodic conversations and review of documents by non-senior staff would allow us to stay up to date. These updates became significantly more involved than we anticipated because there were major developments with each of our top 3 charities (we had not expected any developments that would meaningfully affect our rankings), and these took significant senior staff time to investigate and write up.
    • The Against Malaria Foundation (AMF), our #1-ranked charity in 2011 and 2012, did not finalize a distribution to which it could allocate the bulk of funds it had on hand. This led us to remove AMF from our recommended charities list due to lack of room for more funding (details in this post).
    • We learned new information about the monitoring and evaluation that had provided a substantial part of the case for the Schistosomiasis Control Initiative (SCI), an organization we have recommended since 2011 (details in this post). SCI also significantly improved its communication with us, addressing many of the problems we noted earlier in the year.
    • Researchers released results from a randomized controlled trial of GiveDirectly’s program in late November, providing a key piece of evidence about GiveDirectly’s progarm’s impact (details in this post). This update, while substantial, did not require significant senior staff time.
  • New charity reviews. At the beginning of the year, we did not expect to find new top charities in 2013. In April, we began evaluating the Deworm the World Initiative (led by Evidence Action). Our familiarity with deworming and our existing intervention report on deworming made this investigation easier than it otherwise might have been; the fact that DtWI was the first technical assistance/advocacy organization we had reviewed made this analysis more complicated. In all, this investigation took about as long as we would have expected given that it was a new top charity. This investigation required significant senior staff time, but a substantial portion of that time involved training Timothy Telleen-Lawton, a new hire whom we anticipate requiring reduced oversight in the future. Timothy led the investigation of DtWI and did the bulk of the work on it.
  • Hiring. We made major progress on this goal. In addition to Tim, we hired five new Research Analysts, increasing our capacity for (a) conversation notes processing; (b) “vetting”, i.e., carefully reviewing pages pre-publication to identify any errors; (c) completing intervention reports, something that some of the new hires proved able to do with little involvement from senior staff. We completed new intervention reports on water quality and vitamin A supplementation (forthcoming).
  • Donation processing. While we did not articulate this as a goal for 2013, we significantly improved our donation processing system over the course of the year. Processing donations and metrics from 2012’s giving season had taken approximately 3 full-time months. The improvements we made last year allowed us to process more than twice as many donations using less than half the time we had previously. (We also believe that these changes will scale well as we continue to grow.) These improvements were led by Natalie Crispin and required almost no senior staff time.

The state of our traditional work and major things we learned in 2013
To review, at the beginning of 2013, we felt that our traditional research and recommendations were relatively strong and would remain a valuable resource with limited effort put into improving them. We therefore aimed to limit senior staff time on this work in order to enable progress on GiveWell Labs. We ultimately spent significantly more senior staff time on our traditional work than we had anticipated, which we felt was necessary to maintain the quality of our research, though we did achieve our big-picture goal of allocating more senior staff time to GiveWell Labs and making more progress on that front.

Three major observations from 2013 will inform our plans going forward.

  • Significant growth in attention to/interest in our traditional work. Last year, we saw significant growth in interest in our traditional work from media and donors. At the beginning of last year, we would have guessed that growth would slow, yet we saw significantly more media attention than we had in past years, which contributed to our more than doubling the number of donors giving to our top charities and significant web traffic growth. Both the number of donors (as well as the total amount given by <$5,000 donors) and web traffic grew at a faster rate last year than they had in previous years; growth in donations from larger donors slowed relative to last year’s growth, though this trend is less robust because of the smaller numbers of people involved. (We will share full details on these figures in our forthcoming metrics post.)
  • The challenge of maintaining the quality of our research and recommendations. In early 2013, we expected to spend relatively little time maintaining the quality of our research and recommendations. As discussed above, this did not work out as we had planned, and we no longer believe that we can easily maintain the quality of our research and recommendations without the engagement of highly skilled/trained staff. More broadly, we continued to learn about (and write about) the fundamental difficulty of the “giving as consumption” model underlying our traditional work, and believe that continuing to provide a strong resource using this model could take quite a bit of work and ingenuity going forward.
  • Increased interest from charities in receiving our recommendations. As our money moved has grown, we have seen increased interest from charities in engaging with us and our process. This willingness to engage has grown consistently over the course of GiveWell’s history, but we now believe we have reached a level of money moved where most organizations will seriously consider engaging with us, as opposed to just ignoring us. This should enable us to choose the organizations that we think are most promising; encourage them to apply; and if they choose not to, understand what led them to decline (e.g., insufficient staff time, limited monitoring data, etc.). In the past, charities chose not to participate for reasons we often didn’t fully understand and we hope that this has now changed. This should eventually improve the robustness of our top charities list.

Note 1: In this post, senior staff refers to Elie, Holden, and Alexander.

GiveWell’s progress in 2013

This is the first post (of six) we’re planning to make focused on our self-evaluation and future plans.

As in past years, we’re going to be posting our annual self-evaluation and plan as a series of blog posts. This post summarizes what changed for GiveWell in 2013 and what it means for the future. Future posts will elaborate.

This year, we are separately reviewing our “traditional work” (recommending top charities that focus on evidence-backed programs serving the global poor) and GiveWell Labs (our newer project, on which we work closely with Good Ventures).

For us, the major developments of 2013 were:

  • We continued to see strong growth in money moved and improved media coverage, though we are still working on assembling the details. There was some extent to which larger donors gave less in 2013 than previously, due to saving for future opportunities (potentially including AMF), so we aren’t yet sure what the final figures for larger donors will be, but the overall picture is one of strong growth.
  • We made major progress on building capacity. We made a total of 6 new hires, and these new hires led work on our new top charity review (more below) and on new reports on priority interventions. We also improved our donation processing system, further improving our forward-looking capacity. As a result, our 2014 plan for our traditional work is substantially more ambitious than our 2013 plan was.
  • We added a new top charity (Deworm the World Initiative) and produced substantial updates on our existing top charities, including suspending one recommendation for room-for-more-funding-related reasons.
  • We spent more senior staff time than anticipated on our traditional work (since there were major new developments concerning each of our top charities) as opposed to GiveWell Labs.
  • We made substantial progress on GiveWell Labs: we refined our basic framework and goals, gained some basic familiarity with two major areas of philanthropy (policy-oriented philanthropy and scientific research funding) that we had had little exposure to previously, and examined multiple potential causes at different levels of depth. We are setting a “stretch goal” for 2014 of making substantial commitments (multiple years, substantial funding) to causes within the broad areas of policy-oriented philanthropy and global catastrophic risks.
  • Our traditional work (“top charities”) seems both more challenging and more important than it was a year ago – the former because of how much senior time it continues to take to respond to new developments, the latter because of the increased media coverage and continuing growth in money moved that we saw. We now see a strong possibility that GiveWell Labs eventually will become a separate organization, though it will remain part of GiveWell in the short term. We plan minor steps to begin moving toward a separation, including potentially renaming GiveWell Labs.
  • Fundraising remains a priority. We are currently fundraising for unrestricted support, supporting a team that is allocated flexibly between GiveWell Labs and our more traditional work.

Overall, we consider 2013 to have been a year of substantial progress on research (both GiveWell Labs and our traditional work), staff capacity, and influence. Our 2014 goals will be more concrete and ambitious than our 2013 goals were.

Of course, we also made some mistakes in 2013, and we’ve recently updated our shortcomings log to reflect them. In particular, we produced public updates on AMF too infrequently.

A series of future posts will go into more detail on the above points.

Returns to life sciences funding

[Added August 27, 2014: GiveWell Labs is now known as the Open Philanthropy Project.]

As noted previously, I’ve been investigating the question: How does the “good accomplished per dollar” of life sciences funding compare to that of other giving options (such as LLIN distribution)? At this point, I believe that there is very little in the way of academic literature that can shed light on this question. I’ve put together some very limited and preliminary analysis; to produce something better, I’d want to work with both generalist scientific advisors and at least one economist.

Existing literature
In order to assess the existing literature on returns to life sciences funding, we have:

Our takeaways on the relevance of this literature for our purposes:

  • Some research focuses on the role that general scientific research and technology innovation has played in reductions in the burden of disease, and generally concludes that it has played a major role (see, in particular, Chapter 4 of Measuring the Gains from Medical Research: An Economic Approach, which discusses heart disease, and The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000 which discusses cancer).
  • Some research attempts to disentangle the roles of publicly and privately funded research, and otherwise isolate which kind of research has been responsible for humanitarian gains (and on what timescales); we haven’t found this work compelling.
  • Some research attempts to quantify the economic value of past reductions in disease burden, and juxtapose it with the amount the U.S. spends on public research (without directly estimating how much of the reduction is due to public research). This research generally concludes that benefits are significant and far outweigh the costs. For example, chapter 1 of Measuring the Gains from Medical Research: An Economic Approach argues that the value of improved life expectancy over the last ~100 years (monetized using the value of a statistical life framework) is comparable to total measured GDP growth over that time; chapter 2 estimates that gains from 1970-2000 were worth about $46 trillion total, net of increased spending on health care, as against an NIH budget of ~$35 billion per year as of 1995.
  • Overall, relatively little has been done in this area, and we haven’t found any research that attempts to (a) make forward-looking estimates of the likely future returns to investments in life sciences; (b) estimate the value of the marginal (as opposed to average) dollar spent on research.

An extremely rough forward-looking cost-effectiveness analysis for cancer research
I created a rough forward-looking cost-effectiveness analysis for cancer research, in order to start thinking through what a more sophisticated analysis would look like. The analysis is available here. Note that:

  • I chose to focus on cancer because (a) most of the burden is via mortality rather than morbidity, and I believe mortality statistics to be generally easier to access and verify than morbidity statistics; (b) because cancer is a politically popular disease for research funding, it’s likely that the “official” cancer budget of the NIH is a reasonable proxy for – or perhaps overestimate of – how much is being spent on cancer research. (By contrast, if I focused on a less politically salient disease, I’d worry that I was substantially undercounting the funding directed toward it, as funding that was officially earmarked for more popular diseases could effectively be financing highly relevant research. In the case of cancer, while I expect some research outside the National Cancer Institute to be relevant to cancer, I also expect some National Cancer Institute research to be highly relevant to other diseases, and I think it is not unreasonable to think of the National Cancer Institute budget as approximating the “costs of scientific progress on cancer.”)
  • I would guess that cancer research produces less benefit per dollar spent than research in many other categories, partly because I perceive cancer as having a relatively large amount of interest from funders.
  • This estimate applies only to the average, not marginal, dollar of research funding.
  • I’ve estimated the “future reductions in the burden of cancer attributable to publicly financed research” at 50% based on Dario’s input and some checking of whether this would be consistent with past reductions in the burden of cancer (more in the spreadsheet).
  • I’ve only considered the National Cancer Institute budget; I haven’t considered private philanthropic funding, overseas funding, private R&D costs or potential increased health care costs (though it’s possible that stronger progress on the basic science of cancer could lead to lower R&D costs and health care costs, if it leads to drugs with stronger and easier-to-prove effects).
  • I’ve only considered the U.S. burden of cancer, not the global burden.
  • I’ve only considered mortality, not morbidity.

The estimate is ~$2800 per life-year, which is substantially worse than our estimate of ~$80/DALY for LLIN distribution, but not so much worse as to make it implausible that well-directed scientific research (as opposed to “the average dollar spent on cancer research”) could have greater (even substantially greater) benefits. In order to create a better estimate down the line, I would want to:

  • Focus in on a particular kind of highly promising research, to the extent possible, and attempt to focus on the future impact of the marginal rather than average dollar. This would require views about the best opportunities within life sciences funding and their possible product, of the kind that would require substantial input from scientists.
  • Take private philanthropic, industry, and international funding into account; have a more sophisticated picture both of which funding to count as being “toward” the goal in question.
  • Take the international burden of disease into account, and include morbidity as well as mortality.

Exploring life sciences funding

[Added August 27, 2014: GiveWell Labs is now known as the Open Philanthropy Project.]

As noted previously, I’ve been exploring the question, “What are the best opportunities for funders aiming to contribute to progress in life sciences (i.e., biology and medicine)?” This post lays out what we’ve done to date and how we plan to move forward.

The basic approach I’ve taken: interviews and immersion
Because this area is so different from anything GiveWell has looked at before, I’ve initially tried to “immerse” myself in it: I’ve taken opportunities to have extended and low-stakes interactions with scientists and learn a little bit of the basic knowledge underlying life sciences, without having specific questions or goals in mind.

The most helpful person in this endeavor has been Dario Amodei. Dario is currently a postdoctoral research fellow at Stanford Medical School studying proteomics; he is a recipient of the Hertz Fellowship and winner of the Hertz Foundation’s 2012 Thesis prize for his Ph.D. dissertation in the field of neuroscience. He is also a longtime GiveWell fan and supporter (see his 2009 guest post on the GiveWell blog), and the two of us have been housemates since GiveWell relocated to San Francisco.

For the early stages of investigation, Dario has served as our informal scientific advisor,* guiding our investigation by recommending readings, offering connections, etc. I feel that he has been a good fit for this role because he combines experience as a scientist with an extremely strong understanding of GiveWell’s values and goals, and is highly accessible to us. We’ve come to believe that in the early stages of an investigation, when we often don’t know which questions to ask, the ability to have extended, repeated, friendly, low-stakes interactions to get “grounded in the basics” is crucial, and we’ve taken a similar approach to exploring policy advocacy (which we wrote about previously).

Under Dario’s guidance, I have:

  • Conducted a series of interviews with representatives of major life sciences funders including Howard Hughes Medical Institute (the largest private philanthropic funder of scientific research in the U.S.), Wellcome Trust (the largest private philanthropic funder of life sciences in the U.K., with similar scale to Howard Hughes and to the British government’s research funding), and the American Cancer Society. (We have also had several other off-the-record conversations, including with U.S. government staff.)
  • Studied a small amount of the basics of cell biology. Specifically, I read chapters 1, 5, 6, 7, 8, 18 and 20 from Essential Cell Biology; reviewed the more detailed version of chapter 7; and questioned Dario about them at length. The two of us also discussed the abstracts of several NIH grant proposals and Nature papers. The goal here was simply to improve my basic comprehension of common terms used in discussing life sciences; after the calls discussed above, he and I agreed that it was important for me to improve on this front.
  • Taken opportunities to attend larger meetings of scientists in appropriate settings: relatively low-stakes settings in which communication in layperson’s terms was encouraged. I attended a meeting at the Banbury Center, intended to bring together people with different areas of expertise to discuss possible approaches to oncology; a meeting organized by Good Ventures (with Dario’s help) to discuss potential prizes in science; and several meetings of Vannevar Group. All of these meetings were organized by Dario or people in his network.

Several perspectives on giving opportunities aiming at furthering progress in life sciences
One natural way to look for underfunded opportunities is to focus on the question of “what diseases and conditions should be getting more focus and funding?” It’s possible that some diseases and conditions are overlooked because they primarily affect people in the developing world (for example, malaria and tuberculosis); it’s possible that some are overlooked because they don’t have the same sorts of interest groups behind them (for example, chronic pain and other symptoms of aging, which have no analogue to groups like American Cancer Society). Prior to starting this investigation, this was the main framework we were thinking about for finding overlooked giving opportunities, and we believe there may be a lot of potential in thinking in this way.

However, the interviews we’ve done so far have led us to believe that this is far from the only – and may not be the best – framework for thinking about “what sorts of science are underfunded.” Much scientific research – including many of the discoveries that have been associated with the Nobel Prize – is not clearly associated with a particular disease or condition at all. Conversely, it’s possible that funding officially directed toward a particular disease or condition is instead used for work with more general ambitions. Thinking about “which disease and condition should be targeted” is a natural framework for humanitarian-oriented non-scientists, but it isn’t necessarily the most natural way of dividing up different types of science from a scientist’s perspective.

The interviews we’ve done so far have included several criticisms of the primary existing science funding mechanisms, particularly those of the National Institutes of Health (NIH). The NIH provides over half of all U.S. funding in life sciences, and about half of all NIH funding is via a particular grant mechanism, called the R01. The R01, and the NIH more broadly, is perceived as a major factor in researchers’ incentives, and observations about “what the science world needs more of” seem closely connected with critiques of the NIH and the R01. I refer to the NIH, and particularly the R01, as “the existing” system in the bullet points below, listing some of the claims discussed in our interviews:

  • The existing system favors researchers with strong track records, and is not good at supporting young investigators. This was the most commonly raised concern, and is mentioned in all three of our public interviews.
  • The existing system favors a particular brand of research – generally incremental testing of particular hypotheses – and is less suited to supporting research that doesn’t fit into this mold. Research that doesn’t fit into this mold may include:
    • Very high-risk research representing a small chance of a big breakthrough.
    • Research that focuses on developing improved tools and techniques (for example, better microscopy or better genome sequencing), rather than on directly investigating particular hypotheses.
    • “Translational research” aiming to improve the transition between basic scientific discoveries and clinical applications, and not focused on traditionally “academic” topics (for example, research focusing on predicting drug toxicity).
  • The existing system focuses on time-consuming, paperwork-heavy grant applications for individual investigators; more attention to differently structured grants and grant applications would be welcome. These could include mechanisms focused on providing small amounts of funding, along with feedback on ideas, quickly and with minimal paperwork, as well as mechanisms focused on supporting larger-scale projects that require collaboration between multiple investigators.

We don’t yet endorse any of these claims, and we’re aware that in many cases the NIH has mechanisms that intend to address alleged shortcomings. In order to assess these claims, we feel that we would need staff and/or advisors with substantial technical knowledge, as discussed in the next section.

The centrality of scientific advisors
The basic approach we’re picturing for GiveWell Labs runs roughly as follows:

  1. Generalist GiveWell staff (everyone we currently employ should be thought of as a generalist) gather information on many different causes, through methods including interviewing those with relevant expertise, and seek to understand different causes’ importance, tractability, and “crowdedness” at a high level.
  2. For particularly promising causes, GiveWell will consider hiring staff to specialize in these causes (or recommending that major philanthropists hire staff for this purpose), since we believe that having the appropriate amount of context to evaluate giving opportunities in a cause may take in excess of a year (even with good access to relevant experts).
  3. Generalist staff will be responsible for evaluating cause-specific staff; cause-specific staff will be responsible for synthesizing expert opinion and other information to make giving recommendations. However, when investigating scientific research, we believe that another link in the chain is needed. We believe that we need generalist scientific advisors in order to evaluate and compare different approaches to scientific funding at a high level. This is because, based on the early investigation detailed above, I don’t feel positioned even to understand the meaning – much less the plausibility – of many key claims. For example, in order to evaluate the claim that “high-risk” research is under-invested in, I’d want to be able to distinguish high-risk from lower-risk research and be able to assess how much is invested in each – something that I believe is likely to require substantial technically informed judgment calls. To some degree, this dynamic holds for any cause. In any field, there will be people whose greater experience makes subtle contributions to how they see many debates and evaluate many interventions. But scientific research is distinguished from other fields I’ve investigated by the degree to which expertise (often in the form of understanding a very specific, near-universal knowledge base that requires extended study to absorb) is a prerequisite to understanding the basics of what people are claiming and how one might reasonably go about comparing and drilling down on claims. Therefore, we chose to pause further investigation of scientific research until we recruit an appropriate set of generalist scientific advisors. (We have very recently – as of this week – formed a few new advisory relationships and restarted research.)

What we’re looking for in generalist scientific advisors
What follows is a draft spec that we have started to circulate in search of generalist scientific advisors. We plan to distribute it both within our network and more broadly, and initially Dario and I are evaluating candidates based on scientific aptitude and accomplishments (Dario and his network assess this) and fit with GiveWell (I assess this). So far, we have circulated this spec informally and found a few advisors we are working with on a trial basis; yesterday we started distributing the spec more broadly.

About us
GiveWell (www.givewell.org) finds outstanding giving opportunities and publishes the full details of its analysis to help donors decide where to give. It has historically focused on direct aid, but is now exploring the idea of funding (via recommendation) scientific research. GiveWell works as an advisor to Good Ventures (www.goodventures.org), a foundation funded by Dustin Moskovitz (co-founder of Facebook and, more recently, Asana) and run by Cari Tuna.

GiveWell’s ultimate goal is to accomplish humanitarian good, but it believes that some of the most beneficial scientific breakthroughs will come via long-term, high-risk fundamental research and is highly open to promoting work in this category.

GiveWell is not limited to any particular field, disease, biological condition, or population. We seek to broadly consider and identify the approaches that are most (a) promising and (b) under-invested in by other funders. We are likely to focus initially on life sciences (though this will include other areas with applications to life sciences, e.g., novel measurement platforms), but intend to explore other areas as well. We are seeking both advisors with backgrounds in life sciences and/or physical sciences who think strategically about future implications of fundamental research, with an eye to long-term, transformative impact.

GiveWell seeks scientists who are deeply experienced and (depending on career stage) accomplished, and who are committed to identifying the most promising science, regardless of how unconventional it may be. GiveWell hopes to find opportunities that are potentially transformative, and appear after substantial scrutiny (by world-class scientists) to represent intelligent (if sometimes risky) philanthropic investments.

The role
Generalist scientific advisors will help GiveWell find the best opportunities for a funder to accomplish good – whether it takes the form of pursuing short-term, cost-effective research with direct humanitarian applications, or pursuing long-term, fundamental research aiming for breakthroughs with wide-reaching and difficult-to-predict applications. Activities may include:

  • Interviewing other funders’ staff and scientific advisors to evaluate different approaches to research funding.
  • Finding, interviewing, and evaluating scientists doing particularly promising work.
  • Assessing (via literature review, interviews, etc.) the tractability of particular scientific goals and the likely future progress of particular fields
  • Seeking out, and presenting arguments regarding, inefficiencies in the current infrastructure for funding scientific research

GiveWell expects advisors to serve on a part-time basis, with significant variability in time commitment from week to week. In our early stages, we will likely seek to work with advisors on a trial basis, without long-term commitments. GiveWell’s staff will provide support (scheduling, documentation, etc.) as appropriate.

The team
We expect initially to retain 5-10 scientific advisors, at a variety of career stages (potentially ranging from junior faculty or even postdoctoral fellows to very senior scientists). We are interested in advisors from both academia and industry. This team will interact with each other regularly and bring diverse perspectives to the questions we’re asking. These will not be the only scientists we work with, but they will be the team of “generalists” that has primary responsibility for broad, comparative analysis identifying particularly promising areas and people to invest in.

Qualifications

  • Strong scientific accomplishments for one’s career stage.
  • Technical intelligence, as assessed by both track record and by interviews (with scientists we retain for interviewing).
  • Breadth of interests and abilities. Generalist scientific advisors should be interested in – and good at – comparatively assessing science and scientists in a broad variety of fields.
  • Willingness and ability to think critically and strategically but unconventionally, in order to find the ways in which existing funding infrastructure for science falls short of its potential.
  • Deep and broad network of high-quality scientific colleagues with whom the advisor may consult for specific technical expertise as needed to assess opportunities.
  • Willingness and ability to communicate one’s views to non-technical people, and technical experts outside one’s own scientific field.
  • Interest in assessing the potential connection between scientific progress and humanitarian progress, both over the short and long run.

This is an opportunity to influence the scientific priorities of a potentially major source of funds whose focus is on humanitarian good accomplished, without pre-commitments to particular fields, diseases, conditions, or populations. We are seeking people who are excited by the opportunity to have this influence, passionate about finding opportunities for scientific funders to accomplish good, and accordingly prepared to accept compensation that is reasonable but below what they could earn consulting for for-profit organizations.

* We’ve recently started paying Dario for work that is focused on GiveWell’s priorities. These expenses have fallen under the heading of “independent research contractors,” which are covered by a specially earmarked grant from Good Ventures.

Some considerations against saving for next year

This post is authored by GiveWell staff member Timothy Telleen-Lawton.

In the past we’ve written about some of the advantages of giving early rather than saving for future gifts. This year there seem to be more people in our audience and on our staff interested in saving money with the hopes of having a bigger impact by donating it in the future.

The two basic reasons that giving later may sometimes be better than giving now are a) our greater experience and knowledge in the future may lead us to better opportunities, and b) some good opportunities in the future may not be available today. While I expect both of these to be true to some degree, other factors argue for giving sooner rather than later.

Looking back at GiveWell’s history, for example, I believe that earlier donations to our recommendations were significantly more impactful than later ones. While I believe we’ve steadily gotten better at improving our investigation process and finding outstanding giving opportunities, that wouldn’t have happened without the legitimacy that came from the earlier contributions (although it now seems likely that delaying contributions by a couple years wouldn’t have as much impact on our credibility as it would have in previous years, I think this is still an important factor to consider). Additionally, for any given charity, earlier gifts will likely be more impactful, so even as we’re finding better opportunities, each opportunity we’ve found may have less impact over time.

I think some people are weighing the considerations differently this year than in others, based on a belief that there are especially strong arguments in favor of saving this year and giving next year. I think some of these arguments are valid, but some have been exaggerated.

Is this year special?
Traditional GiveWell recommendations

We may vet a charity in 2014 that ends up being a significantly better giving opportunity than our existing recommendations. While we have made improvements to our process for finding and vetting eligible charities, this has also been true every year for GiveWell, and while we are planning to spend more person-hours on this process in 2014 than 2013, it seems only moderately (not highly) likely that we’ll find a better giving opportunity on this front than our current set. If we do end up recommending a new charity, it will not necessarily need more funds than will be moved to it next year (unlike e.g. GiveDirectly now). Since giving to our current recommendations next year is less impactful than giving to them this year, waiting for a better recommendation is a risk.

The Against Malaria Foundation (AMF)

It seems that the best gamble for a significantly better recommendation within the next year relies on AMF, which is in the unusual position of being off of our recommendations list for a precise reason that could quickly change during this year via completion of a large bed net distribution. Since the evidence of efficacy for bed nets is significantly stronger than that of deworming pills and bednets appear several times more cost effective than cash transfers by our best guesses (more), one could argue for saving some money that would otherwise have been given now to be given at a specific date in the future. This strategy makes more sense to me than donating to AMF now, and is the best argument I can think of for saving rather than giving this year.

GiveWell Labs

Some have also expressed an interest in waiting for opportunities that will come from our GiveWell Labs research. I empathize with this desire since we expect to find opportunities with higher expected value than traditional recommendations (though perhaps never with as much certainty of impact) and expect individuals to eventually contribute to them. However, the generosity and funding potential of Good Ventures put some limits on what sort of room for more funding such opportunities will have in the next few years, even if we develop a mechanism to allow donors to invest alongside Good Ventures before then. There will likely be some room for more funding, but it may not be for the most urgent parts of the funding gaps. So Good Ventures’ resources do remove much of the urgency that would otherwise help justify saving for that time.

I expect to contribute to Labs efforts in the future, but saving for several years seems too risky considering that our recommendations can make good use of money now. For those intent on using donations this year to help GiveWell Labs work, you can also donate to GiveWell.

Modeling versus engineering
I may put more weight on annual giving than some in the effective altruist movement in part because I think we will be better served by modeling the behavior we want to spread, rather than by each of us trying to directly engineer the world outcome we want to see (in this case the precise allocation that will maximize long term impact). The former is something we have more control over, and is more important if most of our long term impact will come from individuals not yet part of this young movement. From this perspective, having a simple, robust heuristic that scales well is a major asset. I see ‘giving what you can each year, to the best opportunities you can find’ to be such a heuristic, so I hold a high bar for breaking it.